Levels of soluble fas/APO‐1 /CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis
- 9 December 1995
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 38 (12) , 1735-1737
- https://doi.org/10.1002/art.1780381205
Abstract
Objective. To quantify soluble Fas/APO‐1 (sFas/APO‐1 ) protein in the serum of patients with systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA). Methods. Soluble Fas/APO‐1 was quantified using a sandwich enzyme‐linked immunosorbent assay. Disease activity in SLE patients was assessed by the SLE Disease Activity Index. Results. Increased serum sFas/APO‐1 levels were observed in only 1 of the 27 SLE patients (4%) and 3 of the 10 JRA patients (30%). Conclusion. Increased levels of sFas/APO‐1 occurred infrequently in SLE, and the levels were lower than 10 ng/ml. Increased levels of sFas/APO‐1 are not specific for SLE. Soluble Fas/APO‐1 is unlikely to be of major pathogenetic significance in SLE.Keywords
This publication has 10 references indexed in Scilit:
- Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemiasBlood, 1995
- Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)Nature, 1995
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994
- The apoptosis-1/Fas protein in human systemic lupus erythematosus.Journal of Clinical Investigation, 1994
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosisNature, 1992
- Molecular cloning and expression of a receptor for human tumor necrosis factorCell, 1990
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982